Sun Jianguo, Deng Li, Duan Yuzhong, Chen Fanglin, Wang Xinxin, Li Dezhi, Chen Zhengtang
Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing 400037;
Exp Ther Med. 2012 Feb;3(2):159-164. doi: 10.3892/etm.2011.384. Epub 2011 Nov 18.
In the present study, we aimed to investigate the tumor-inhibiting effects of recombinant human endostatin (rhES) combined with paclitaxel-cisplatin (TP regimen) on human breast cancer in xenograft-bearing nude mice. A total of 24 mice bearing human breast cancer xenografts were administered both rhES and TP, TP alone, rhES alone or saline. The tumor growth inhibition was observed. Serum vascular endothelial growth factor (VEGF) levels and microvessel density (MVD) were determined by ELISA and immunohistochemistry, respectively. Cell apoptosis was detected using terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) staining. Survival time was observed in another 24 nude mice with the same treatment. MVD expression in the group administered rhES and TP was lower than that in the other groups (P<0.05); serum VEGF levels in the combined drug group were lower compared to the other groups; the apoptotic index increased in the combined drug group. We conclude that the effect of the TP regimen combined with rhES on breast cancer is better than that of the TP regimen alone.
在本研究中，我们旨在探讨重组人内皮抑素（rhES）联合紫杉醇-顺铂（TP方案）对荷人乳腺癌异种移植裸鼠的抑瘤作用。总共24只荷人乳腺癌异种移植瘤的小鼠分别接受rhES与TP联合治疗、单纯TP治疗、单纯rhES治疗或生理盐水治疗。观察肿瘤生长抑制情况。分别采用酶联免疫吸附测定（ELISA）和免疫组织化学法测定血清血管内皮生长因子（VEGF）水平和微血管密度（MVD）。使用末端脱氧核苷酸转移酶dUTP缺口末端标记（TUNEL）染色检测细胞凋亡。对另外24只接受相同治疗的裸鼠观察生存时间。rhES与TP联合治疗组的MVD表达低于其他组（P<0.05）；联合用药组的血清VEGF水平低于其他组；联合用药组的凋亡指数升高。我们得出结论，TP方案联合rhES对乳腺癌的疗效优于单纯TP方案。
